[ad_1]
This week, meeting news from the American Heart Association Scientific Sessions were the most-read stories in cardiology. Coverage of the meeting highlighted methods to improve CVD prevention, CV care and issues affecting patients and providers. New cholesterol guidelines that emphasized novel medications and more personalized risk calculation were also presented at the meeting.
Presentations featured several clinical trials. Findings from these trials demonstrated that icosapent ethyl reduces ischemic events in high-risk patients, dapagliflozin reduces heart failure hospitalization in patients with type 2 diabetes and vitamin D and omega-3 fail to reduce major CV events and cancer.
Prevention takes center stage at American Heart Association Scientific Sessions
The American Heart Association Scientific Sessions, being held from Nov. 10 to 12 in Chicago, will include the release of two major guidelines focusing on cholesterol and physical activity, the presentation of important science on CVD prevention, a focus on the use of technology to improve CV care and a high-level overview of issues affecting patients and providers. Read more.
Cholesterol guidelines updated with newer medications, more personalized risk calculation
CHICAGO — New cholesterol guidelines from the American Heart Association, American College of Cardiology and 10 other societies recommend a stepped approach, including statins, ezetimibe and PCSK9 inhibitors in patients with prior CVD at very high risk for another event. Read more.
REDUCE-IT: Icosapent ethyl reduces ischemic events in high-risk patients
CHICAGO — In patients with elevated triglycerides at high CV risk despite statin therapy, icosapent ethyl was superior to placebo for reducing risk for ischemic events, according to results of the anticipated REDUCE-IT trial. Read more.
DECLARE-TIMI 58: Dapagliflozin reduces heart failure hospitalization in type 2 diabetes
CHICAGO — The DECLARE-TIMI 58 trial of dapagliflozin in patients with type 2 diabetes who had or were at high risk for atherosclerotic CVD adds to the growing body of evidence that demonstrates the favorable effects of SGLT2 inhibitors on CV risk. Read more.
VITAL: Vitamin D, omega-3 fail to reduce major CV events, cancer
CHICAGO — In the large-scale VITAL trial, neither omega-3 nor vitamin D supplements for primary prevention reduced major CV events or development of invasive cancers compared with placebo over 5 years of follow-up. Read more.
[ad_2]
Source link
